Comparison

Zonisamide European Partner

Item no. TMO-T0267-500mg
Manufacturer TargetMol
CASRN 68291-97-4
Amount 500 mg
Quantity options 100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 mL 200 mg 25 mg 2 mg 500 mg 50 mg
Category
Type Molecules
Specific against other
Citations 1. Tsujii S, et al. Eur J Pharmacol. 2015 Jan 5;746:301-7.
Smiles C(S(N)(=O)=O)C=1C=2C(ON1)=CC=CC2
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Alias AD 810,CI 912
Shipping Condition Cool pack
Available
Manufacturer - Targets
Calcium Channel|||Sodium Channel|||Carbonic Anhydrase
Shipping Temperature
Cool pack
Storage Conditions
-20
Molecular Weight
212.23
Description
Zonisamide (AD 810), a sulfonamide anticonvulsant, is approved for use as an adjunctive treatment in adults with partial-onset seizures. It may inhibit a carbonic anhydrase although this is not one of the main mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels results in a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may lower the uptake of the inhibitory neurotransmitter GABA while increasing the uptake of the excitatory neurotransmitter glutamate.
Pathways
Membrane transporter/Ion channel|||Metabolism

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close